NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Questex's Fierce Biotech today announces the finalists of the second annual Fierce ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $9.83, a high estimate of $15.00, and a low estimate of $5.00. A decline of 39.21% ...

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were trading at $30.25, down $5.60, or 15%, on word of the delay of data from the phase III X-tole2 trial with azetukalner in focal onset seizures ...

Discover Fortrea Holdings Inc.'s Q1 2025 earnings insights, including reaffirmed guidance, cost-saving initiatives, and biotech pipeline growth amid ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell ...

According to TipRanks.com, Werber is a 4-star analyst with an average return of 7.6% and a 49.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical ...